Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tarceva Expanded Access Program in Advanced NSCLC
NCT00949910Phase 4Completed
- Sponsor
- Roche
- Start
- Nov 2004
- Primary completion
- Apr 2009
- Modality
- Small Molecules
- Countries
- 51
01
Overview
Phase 4, open-label, single-arm trial of erlotinib in non-small cell lung cancer (NSCLC), sponsored by Roche. Primary endpoint: Objective Response Rate up to 4.5 years. Started Nov 2004; status: completed.
02
Drugs
erlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00949910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00949910.